ascendis
pharma
announces
presentations
pth
hypoparathyroidism
american
society
bone
mineral
research
annual
meeting
copenhagen
denmark
globe
newswire
ascendis
pharma
nasdaq
asnd
biopharmaceutical
company
utilizes
innovative
transcon
technologies
address
unmet
medical
needs
today
announced
three
presentations
transcon
pth
program
hypoparathyroidism
hp
american
society
bone
mineral
research
asbmr
annual
meeting
virtual
event
taking
place
september
addition
results
randomized
phase
path
forward
trial
presented
scientific
forum
first
time
aliya
khan
selected
presentation
highlights
asbmr
meeting
john
bilezikian
friday
september
pt
excited
asbmr
chosen
highlight
results
fixed
dose
portion
path
forward
trial
study
demonstrated
transcon
pth
eliminated
standard
care
active
vitamin
mg
per
day
calcium
supplements
percent
subjects
across
dosage
said
khan
primary
investigator
clinical
professor
department
medicine
divisions
endocrinology
metabolism
geriatric
medicine
mcmaster
university
ontario
canada
also
found
transcon
pth
demonstrated
improvement
physical
mental
wellbeing
assessed
validated
health
importantly
results
consistent
clinically
meaningful
improvement
functional
health
wellbeing
subjects
receiving
transcon
pth
compared
placebo
four
also
presented
asbmr
results
voices
hypara
survey
done
collaboration
hypoparathyroidism
association
hpa
key
finding
survey
patients
experienced
calcium
crashes
last
year
almost
half
participants
visited
emergency
room
urgent
care
address
hp
symptoms
despite
treatment
standard
survey
illustrates
challenging
people
hp
due
causes
including
diagnosis
managing
daily
symptoms
complications
said
bob
sanders
chairman
board
hypoparathyroidism
association
urgently
need
effective
treatment
options
improve
overall
health
outcomes
people
look
forward
partnering
medical
community
raise
awareness
hp
ensure
patients
access
treatments
presentation
details
asbmr
annual
meeting
virtual
event
oral
presentation
title
date
time
results
path
forward
phase
trial
demonstrating
potential
transcon
pth
replacement
therapy
hypoparathyroidism
tuesday
september
pm
et
poster
presentations
title
date
time
validation
hypoparathyroidism
patient
experience
scale
hpes
understanding
assessing
burden
disease
friday
september
september
voices
hypopara
survey
journey
patients
living
hypoparathyroidism
posters
available
ascendis
website
selected
publications
pipeline
section
https
publications
healthcare
provider
would
like
information
please
contact
medicalaffairs
transcon
pth
transcon
pth
investigational
prodrug
parathyroid
hormone
pth
development
treatment
adult
hypoparathyroidism
hp
designed
replace
pth
physiologic
levels
hours
day
address
symptoms
complications
disease
transcon
pth
granted
orphan
drug
designation
odd
food
drug
administration
fda
june
hypoparathyroidism
hp
hypoparathyroidism
hp
rare
endocrine
disorder
characterized
insufficient
levels
parathyroid
hormone
pth
resulting
low
calcium
elevated
phosphate
levels
blood
hp
affects
approximately
patients
united
states
europe
japan
south
korea
majority
develop
condition
following
damage
accidental
removal
parathyroid
glands
thyroid
surgery
patients
often
experience
decreased
quality
life
short
term
symptoms
include
weakness
severe
muscle
cramps
tetany
abnormal
sensations
tingling
burning
numbness
paresthesia
memory
loss
impaired
judgment
headache
long
term
complex
disorder
increase
risk
major
complications
extraskeletal
calcium
depositions
occurring
within
brain
lens
eye
kidneys
lead
impaired
renal
function
recently
hp
remained
among
hormonal
insufficiency
states
treated
replacement
missing
hormone
standard
care
active
vitamin
analogs
calcium
supplementation
fully
control
disease
may
contribute
risk
renal
disease
result
patients
hp
estimated
greater
risk
renal
disease
compared
healthy
controls
technology
transcon
refers
transient
proprietary
transcon
platform
innovative
technology
create
new
therapies
designed
potentially
optimize
therapeutic
effect
including
efficacy
safety
dosing
frequency
transcon
molecules
three
components
unmodified
parent
drug
inert
carrier
protects
linker
temporarily
binds
two
bound
carrier
inactivates
shields
parent
drug
clearance
injected
body
physiologic
conditions
ph
temperature
initiate
release
active
unmodified
parent
drug
predictable
manner
parent
drug
unmodified
original
mode
action
expected
maintained
transcon
technology
applied
broadly
protein
peptide
small
molecule
multiple
therapeutic
areas
used
systemically
locally
ascendis
pharma
ascendis
pharma
applying
innovative
platform
technology
build
leading
fully
integrated
biopharma
company
focused
making
meaningful
difference
patients
lives
guided
core
values
patients
science
passion
company
utilizes
technologies
create
new
potentially
therapies
ascendis
pharma
currently
pipeline
three
independent
endocrinology
rare
disease
product
candidates
clinical
development
advancing
oncology
second
therapeutic
area
focus
company
continues
expand
additional
therapeutic
areas
address
unmet
patient
needs
ascendis
headquartered
copenhagen
denmark
additional
offices
heidelberg
berlin
germany
palo
alto
redwood
city
california
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
statements
historical
facts
included
press
release
regarding
ascendis
future
operations
plans
objectives
management
statements
examples
statements
include
limited
statements
relating
ascendis
ability
apply
platform
technology
build
leading
fully
integrated
biopharma
company
ii
ascendis
product
pipeline
expansion
additional
therapeutic
areas
iii
ascendis
expectations
regarding
ability
utilize
transcon
technologies
create
new
potentially
therapies
ascendis
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
statements
ascendis
makes
including
following
unforeseen
safety
efficacy
results
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
unforeseen
expenses
related
development
potential
commercialization
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
selling
general
administrative
expenses
research
development
expenses
ascendis
business
generally
delays
development
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
related
manufacturing
regulatory
requirements
speed
patient
recruitment
unforeseen
delays
dependence
third
party
manufacturers
supply
study
drug
planned
clinical
studies
ascendis
ability
obtain
additional
funding
needed
support
business
activities
effects
business
worldwide
pandemic
description
risks
uncertainties
could
cause
actual
results
differ
expressed
statements
well
risks
relating
ascendis
business
general
see
ascendis
prospectus
supplement
filed
july
ascendis
current
future
reports
filed
submitted
securities
exchange
commission
sec
including
annual
report
form
filed
sec
april
statements
reflect
potential
impact
future
collaborations
acquisitions
mergers
dispositions
joint
ventures
investments
ascendis
may
enter
make
ascendis
assume
obligation
update
statements
except
required
law
ascendis
ascendis
pharma
ascendis
pharma
logo
company
logo
transcon
trademarks
owned
ascendis
pharma
group
september
ascendis
pharma
investor
contact
media
contact
patti
bank
ron
rogers
westwicke
partners
ascendis
pharma
rrs
ir
khan
et
al
american
society
bone
mineral
research
annual
meeting
oral
presentation
maruish
e
user
manual
health
survey
lincoln
ri
qualitymetric
incorporated
astolfi
et
al
american
society
bone
mineral
research
annual
meeting
abstract
poster
mannstadt
et
al
nature
reviews
ascendis
pharma
hp
patient
experience
research
hadker
n
et
al
endo
pract
powers
j
et
al
j
bone
miner
res
mitchell
dm
et
al
j
clin
endocrinol
metab
underbjerg
l
et
al
j
bone
miner
res
